Eugene Lam

Biographic Data

ID7028890
NAMEEugene Lam
GIVEN NAMESEugene
FAMILY NAMELam
SIGNATURELAM E
AFFILIATIONSCenters for Disease Control and Prevention
ORCID0000-0003-4332-3267
VERIFIEDYes
TOTAL WORKS6
TOTAL CITATIONS0
WORKS AS AUTHOR6
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2011
LATEST PUBLICATION YEAR2025
H-INDEX0

  • A feasibility study

    Open AccessTalya Shragai, Christina Riley et al.ARTICLEPLOS Global Public Health2025

    Routine collection of behavioral and social drivers (BeSD) of vaccination data is essential for understanding and addressing vaccine confidence and demand to achieve high vaccination coverage. Traditional house-to-house data collection methods are resource-intensive, prompting the need for alternative, scalable approaches. This study tested the feasibility of using mobile phone surveys to collect community-level BeSD data on COVID-19 vaccination …

  • Strengthening the WHO Regional Office for Africa (WHO Afro) Covid-19 vaccination information system

    Open AccessTalya Shragai, Arish Bukhari et al.ARTICLEBMJ Global Health2024

    This manuscript describes the process and impact of strengthening the WHO Regional Office for Africa (WHO AFRO)’s COVID-19 vaccination information system. This system plays a critical role in tracking vaccination coverage, guiding resource allocation and supporting vaccination campaign roll-out for countries in the African region. Recognising existing data management issues, including complex reporting prone to human error, compromised data quali…

  • Implementation of data triangulation and dashboard development for Covid-19 vaccine adverse event following immunisation (Aefi) data in Nigeria

    Open AccessTalya Shragai, Oluwasegun Joel Adegoke et al.ARTICLEBMJ Global Health2023

    Nigeria began administering COVID-19 vaccines on 5 March 2021 and is working towards the WHO’s African regional goal to fully vaccinate 70% of their eligible population by December 2022. Nigeria’s COVID-19 vaccination information system includes a surveillance system for COVID-19 adverse events following immunisation (AEFI), but as of April 2021, AEFI data were being collected and managed by multiple groups and lacked routine analysis and use for…

  • Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region

    Open AccessJoseph M Reardon, Siobhán O’connor et al.ARTICLEConflict and Health2019

    Based on our model, addition of HepB BD vaccination is very cost-effective among three sub-Saharan refugee populations, using relative life-years saved. This analysis shows the potential benefit of implementing HepB BD vaccination among other camp-based refugee populations as more AFR countries introduce national HepB BD policies

  • Displaced populations due to humanitarian emergencies and its impact on global eradication and elimination of vaccine-preventable diseases

    Open AccessEugene Lam, Michael R Diaz et al.ARTICLEConflict and Health2016

    Populations affected by humanitarian emergencies may require unique strategies to ensure access to life-saving vaccines and attain sufficiently high population immunity to interrupt virus circulation. Vaccination strategies among displaced populations should not be an afterthought and must be part of the vaccine-preventable disease eradication and elimination initiatives from the start

  • Highly active anti-retroviral therapy in the prevention of mother-to-child transmission of HIV in rural Zimbabwe during the socio-economic crisis

    Paul Thistle, Shelly Bolotin et al.ARTICLEMedicine Conflict & Survival2011

    The purpose of this study is to evaluate the effectiveness of highly active antiretroviral therapy (HAART) in preventing mother-to-child transmission (PMTCT) of HIV in breastfeeding women in rural Zimbabwe. During a severe socio-economic crisis in 2005-2007, 82 eligible HIV-positive pregnant women between 14-36 weeks gestation were initiated on HAART with AZT/3TC/nelfinavir combination therapy at a rural hospital and continued through to six mont…